Home>>Signaling Pathways>> Others>>Abacavir hydroxyacetate

Abacavir hydroxyacetate

Catalog No.GC66453

Abacavir hydroxyacetate is an orally active inhibitor of IL-20 and PRINS. Abacavir hydroxyacetate reduces proliferation rate of skin in psoriasis as an immune modulator. Abacavir hydroxyacetate can be used for the research of inflammatory skin problems.

Products are for research use only. Not for human use. We do not sell to patients.

Abacavir hydroxyacetate Chemical Structure

Cas No.: 1446418-48-9

Size Price Stock Qty
5mg
$117.00
In stock
10mg
$198.00
In stock
25mg
$432.00
In stock
50mg
$738.00
In stock
100mg
$1,170.00
In stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Customer Reviews

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Abacavir hydroxyacetate is an orally active inhibitor of IL-20 and PRINS. Abacavir hydroxyacetate reduces proliferation rate of skin in psoriasis as an immune modulator. Abacavir hydroxyacetate can be used for the research of inflammatory skin problems[1][2].

Abacavir hydroxyacetate (10-20 mg/kg; p.o. once) effectively controls psoriasis of mice[2].

Animal Model: 6 to 8-week-old male and female SCID mice with implantation of psoriatic tissue[2]
Dosage: 10 and 20 mg/kg
Administration: Oral gavage; 10-20 mg/kg once
Result: Decreased the concentration of PRINS and 1L-20, and reduced the lesion area of skin. Showed a better effect than methotrexate in controlling psoriasis.

Reviews

Review for Abacavir hydroxyacetate

Average Rating: 5 ★★★★★ (Based on Reviews and 30 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Abacavir hydroxyacetate

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.